Annual SGA
$275.27 M
+$62.23 M+29.21%
December 31, 2023
Summary
- As of February 8, 2025, FOLD annual SGA is $275.27 million, with the most recent change of +$62.23 million (+29.21%) on December 31, 2023.
- During the last 3 years, FOLD annual SGA has risen by +$118.86 million (+76.00%).
- FOLD annual SGA is now at all-time high.
Performance
FOLD SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$75.11 M
+$1.53 M+2.08%
September 30, 2024
Summary
- As of February 8, 2025, FOLD quarterly SGA is $75.11 million, with the most recent change of +$1.53 million (+2.08%) on September 30, 2024.
- Over the past year, FOLD quarterly SGA has increased by +$9.46 million (+14.40%).
- FOLD quarterly SGA is now -14.68% below its all-time high of $88.03 million, reached on March 31, 2024.
Performance
FOLD Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$10.92 B
-$104.69 M-0.97%
September 30, 2024
Summary
- As of February 8, 2025, FOLD TTM SGA is -$10.92 billion, with the most recent change of -$104.69 million (-0.97%) on September 30, 2024.
- Over the past year, FOLD TTM SGA has dropped by -$11.18 billion (-4311.13%).
- FOLD TTM SGA is now -29157.70% below its all-time high of -$37.32 million.
Performance
FOLD TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
FOLD Selling, General & Administrative Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +29.2% | +14.4% | -4311.1% |
3 y3 years | +76.0% | +14.4% | -4311.1% |
5 y5 years | +116.4% | +14.4% | -4311.1% |
FOLD Selling, General & Administrative Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +42.8% | -14.7% | +58.9% | -24.3% | at low |
5 y | 5-year | at high | +76.0% | -14.7% | +116.7% | -65.5% | at low |
alltime | all time | at high | +3902.8% | -14.7% | +2535.3% | <-9999.0% | at low |
Amicus Therapeutics Selling, General & Administrative Expenses History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $75.11 M(+2.1%) | $306.95 M(+3.2%) |
Jun 2024 | - | $73.58 M(-16.4%) | $297.50 M(+2.8%) |
Mar 2024 | - | $88.03 M(+25.3%) | $289.34 M(+5.1%) |
Dec 2023 | $275.27 M(+29.2%) | $70.24 M(+7.0%) | $275.27 M(+6.2%) |
Sep 2023 | - | $65.65 M(+0.3%) | $259.31 M(+7.6%) |
Jun 2023 | - | $65.42 M(-11.5%) | $240.93 M(+5.3%) |
Mar 2023 | - | $73.96 M(+36.3%) | $228.88 M(+7.4%) |
Dec 2022 | $213.04 M(+10.6%) | $54.27 M(+14.8%) | $213.04 M(-1.5%) |
Sep 2022 | - | $47.27 M(-11.4%) | $216.37 M(+0.5%) |
Jun 2022 | - | $53.38 M(-8.2%) | $215.20 M(+5.4%) |
Mar 2022 | - | $58.12 M(+0.9%) | $204.10 M(+5.9%) |
Dec 2021 | $192.71 M(+23.2%) | $57.60 M(+24.9%) | $192.71 M(+7.8%) |
Sep 2021 | - | $46.11 M(+9.1%) | $178.79 M(+4.8%) |
Jun 2021 | - | $42.28 M(-9.5%) | $170.54 M(+4.7%) |
Mar 2021 | - | $46.73 M(+7.0%) | $162.92 M(+4.2%) |
Dec 2020 | $156.41 M(-7.9%) | $43.69 M(+15.4%) | $156.41 M(+0.2%) |
Sep 2020 | - | $37.85 M(+9.2%) | $156.02 M(-1.2%) |
Jun 2020 | - | $34.66 M(-13.8%) | $157.85 M(-4.8%) |
Mar 2020 | - | $40.22 M(-7.1%) | $165.77 M(-2.4%) |
Dec 2019 | $169.86 M(+33.5%) | $43.30 M(+9.1%) | $169.86 M(+2.7%) |
Sep 2019 | - | $39.68 M(-6.8%) | $165.33 M(+5.0%) |
Jun 2019 | - | $42.58 M(-3.9%) | $157.51 M(+9.3%) |
Mar 2019 | - | $44.30 M(+14.3%) | $144.11 M(+13.3%) |
Dec 2018 | $127.20 M(+43.5%) | $38.77 M(+21.6%) | $127.20 M(+8.7%) |
Sep 2018 | - | $31.87 M(+9.2%) | $117.02 M(+9.6%) |
Jun 2018 | - | $29.17 M(+6.5%) | $106.80 M(+10.2%) |
Mar 2018 | - | $27.40 M(-4.1%) | $96.94 M(+9.3%) |
Dec 2017 | $88.67 M(+24.6%) | $28.58 M(+32.0%) | $88.67 M(+12.6%) |
Sep 2017 | - | $21.65 M(+12.1%) | $78.77 M(+5.6%) |
Jun 2017 | - | $19.31 M(+0.9%) | $74.59 M(+0.0%) |
Mar 2017 | - | $19.13 M(+2.4%) | $74.58 M(+4.8%) |
Dec 2016 | $71.15 M(+50.5%) | $18.68 M(+6.9%) | $71.15 M(+2.1%) |
Sep 2016 | - | $17.47 M(-9.5%) | $69.66 M(+3.1%) |
Jun 2016 | - | $19.30 M(+22.9%) | $67.56 M(+19.5%) |
Mar 2016 | - | $15.70 M(-8.7%) | $56.54 M(+19.6%) |
Dec 2015 | $47.27 M | $17.19 M(+11.8%) | $47.27 M(+32.8%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2015 | - | $15.37 M(+85.7%) | $35.59 M(+39.6%) |
Jun 2015 | - | $8.28 M(+28.8%) | $25.49 M(+16.0%) |
Mar 2015 | - | $6.43 M(+16.5%) | $21.97 M(+6.0%) |
Dec 2014 | $20.72 M(+9.7%) | $5.52 M(+4.7%) | $20.72 M(+4.6%) |
Sep 2014 | - | $5.27 M(+10.9%) | $19.80 M(+3.3%) |
Jun 2014 | - | $4.75 M(-8.2%) | $19.17 M(-0.4%) |
Mar 2014 | - | $5.18 M(+12.4%) | $19.25 M(+1.9%) |
Dec 2013 | $18.89 M(-2.4%) | $4.61 M(-0.6%) | $18.89 M(+0.8%) |
Sep 2013 | - | $4.63 M(-4.0%) | $18.74 M(-1.9%) |
Jun 2013 | - | $4.83 M(+0.1%) | $19.10 M(-4.9%) |
Mar 2013 | - | $4.82 M(+8.3%) | $20.09 M(+3.8%) |
Dec 2012 | $19.36 M(-2.6%) | $4.46 M(-10.8%) | $19.36 M(+2.9%) |
Sep 2012 | - | $5.00 M(-14.2%) | $18.83 M(+0.8%) |
Jun 2012 | - | $5.82 M(+42.1%) | $18.67 M(-4.6%) |
Mar 2012 | - | $4.09 M(+4.5%) | $19.57 M(-1.5%) |
Dec 2011 | $19.88 M(+26.9%) | $3.92 M(-19.1%) | $19.88 M(+0.5%) |
Sep 2011 | - | $4.84 M(-28.0%) | $19.79 M(+5.0%) |
Jun 2011 | - | $6.72 M(+52.7%) | $18.84 M(+16.7%) |
Mar 2011 | - | $4.40 M(+15.1%) | $16.14 M(+3.0%) |
Dec 2010 | $15.66 M(-21.6%) | $3.82 M(-1.8%) | $15.66 M(-3.2%) |
Sep 2010 | - | $3.89 M(-3.2%) | $16.18 M(-7.6%) |
Jun 2010 | - | $4.02 M(+2.4%) | $17.50 M(-6.4%) |
Mar 2010 | - | $3.92 M(-9.5%) | $18.70 M(-6.4%) |
Dec 2009 | $19.97 M(+1.6%) | $4.34 M(-16.8%) | $19.97 M(-3.2%) |
Sep 2009 | - | $5.22 M(-0.1%) | $20.63 M(+4.3%) |
Jun 2009 | - | $5.22 M(+0.5%) | $19.78 M(+0.5%) |
Mar 2009 | - | $5.20 M(+4.1%) | $19.67 M(+0.0%) |
Dec 2008 | $19.67 M(+28.7%) | $4.99 M(+14.2%) | $19.66 M(-1.5%) |
Sep 2008 | - | $4.37 M(-14.6%) | $19.96 M(+2.1%) |
Jun 2008 | - | $5.12 M(-1.3%) | $19.54 M(+11.0%) |
Mar 2008 | - | $5.19 M(-1.9%) | $17.61 M(+15.3%) |
Dec 2007 | $15.28 M(+24.4%) | $5.28 M(+33.6%) | $15.28 M(+52.9%) |
Sep 2007 | - | $3.95 M(+24.0%) | $9.99 M(+65.5%) |
Jun 2007 | - | $3.19 M(+11.9%) | $6.04 M(+111.9%) |
Mar 2007 | - | $2.85 M | $2.85 M |
Dec 2006 | $12.28 M(+78.5%) | - | - |
Dec 2005 | $6.88 M | - | - |
FAQ
- What is Amicus Therapeutics annual SGA?
- What is the all time high annual SGA for Amicus Therapeutics?
- What is Amicus Therapeutics annual SGA year-on-year change?
- What is Amicus Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly SGA year-on-year change?
- What is Amicus Therapeutics TTM SGA?
- What is the all time high TTM SGA for Amicus Therapeutics?
- What is Amicus Therapeutics TTM SGA year-on-year change?
What is Amicus Therapeutics annual SGA?
The current annual SGA of FOLD is $275.27 M
What is the all time high annual SGA for Amicus Therapeutics?
Amicus Therapeutics all-time high annual SGA is $275.27 M
What is Amicus Therapeutics annual SGA year-on-year change?
Over the past year, FOLD annual SGA has changed by +$62.23 M (+29.21%)
What is Amicus Therapeutics quarterly SGA?
The current quarterly SGA of FOLD is $75.11 M
What is the all time high quarterly SGA for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly SGA is $88.03 M
What is Amicus Therapeutics quarterly SGA year-on-year change?
Over the past year, FOLD quarterly SGA has changed by +$9.46 M (+14.40%)
What is Amicus Therapeutics TTM SGA?
The current TTM SGA of FOLD is -$10.92 B
What is the all time high TTM SGA for Amicus Therapeutics?
Amicus Therapeutics all-time high TTM SGA is -$37.32 M
What is Amicus Therapeutics TTM SGA year-on-year change?
Over the past year, FOLD TTM SGA has changed by -$11.18 B (-4311.13%)